Rebecca Straus Farber

898 total citations
30 papers, 652 citations indexed

About

Rebecca Straus Farber is a scholar working on Pathology and Forensic Medicine, Neurology and Infectious Diseases. According to data from OpenAlex, Rebecca Straus Farber has authored 30 papers receiving a total of 652 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pathology and Forensic Medicine, 11 papers in Neurology and 6 papers in Infectious Diseases. Recurrent topics in Rebecca Straus Farber's work include Multiple Sclerosis Research Studies (19 papers), SARS-CoV-2 and COVID-19 Research (5 papers) and Peripheral Neuropathies and Disorders (5 papers). Rebecca Straus Farber is often cited by papers focused on Multiple Sclerosis Research Studies (19 papers), SARS-CoV-2 and COVID-19 Research (5 papers) and Peripheral Neuropathies and Disorders (5 papers). Rebecca Straus Farber collaborates with scholars based in United States and Slovakia. Rebecca Straus Farber's co-authors include Shailendra Kumar, Ralph Weichselbaum, Donald Küfe, Ajit Bharti, Atsuko Nakazawa, Pramod S. Pandey, Carlo M. Nalin, Surender Kharbanda, Asaff Harel and Fred Lublin and has published in prestigious journals such as Brain, Neurology and Oncogene.

In The Last Decade

Rebecca Straus Farber

30 papers receiving 644 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rebecca Straus Farber United States 12 298 179 100 82 78 30 652
Yanbo Yang China 17 424 1.4× 118 0.7× 158 1.6× 33 0.4× 26 0.3× 55 926
Michael D. Carrithers United States 15 454 1.5× 180 1.0× 68 0.7× 234 2.9× 105 1.3× 39 1.1k
Ferenc Garzuly Hungary 13 393 1.3× 159 0.9× 194 1.9× 90 1.1× 49 0.6× 37 918
Barbara Teuchner Austria 16 139 0.5× 135 0.8× 76 0.8× 40 0.5× 21 0.3× 40 707
K.M. Anderson United States 17 274 0.9× 102 0.6× 48 0.5× 53 0.6× 88 1.1× 40 971
Vera Lehmensiek Germany 15 212 0.7× 251 1.4× 269 2.7× 67 0.8× 84 1.1× 22 848
Mats Ferm Sweden 11 246 0.8× 80 0.4× 34 0.3× 52 0.6× 73 0.9× 17 613
Marta Misiuk‐Hojło Poland 17 208 0.7× 52 0.3× 77 0.8× 69 0.8× 24 0.3× 100 927
Kyoko Ishida Japan 23 140 0.5× 190 1.1× 107 1.1× 85 1.0× 31 0.4× 94 1.7k
Junxian Zhang China 16 240 0.8× 37 0.2× 125 1.3× 54 0.7× 74 0.9× 45 792

Countries citing papers authored by Rebecca Straus Farber

Since Specialization
Citations

This map shows the geographic impact of Rebecca Straus Farber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca Straus Farber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca Straus Farber more than expected).

Fields of papers citing papers by Rebecca Straus Farber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca Straus Farber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca Straus Farber. The network helps show where Rebecca Straus Farber may publish in the future.

Co-authorship network of co-authors of Rebecca Straus Farber

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca Straus Farber. A scholar is included among the top collaborators of Rebecca Straus Farber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca Straus Farber. Rebecca Straus Farber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Farber, Rebecca Straus, Fatoumata Diallo, Claire Riley, et al.. (2024). A randomized cross-over trial of prebiotics and probiotics in multiple sclerosis: Trial feasibility, supplement tolerability and symptom abatement. Multiple Sclerosis and Related Disorders. 89. 105762–105762. 5 indexed citations
2.
Amezcua, Lilyana, Yang Mao‐Draayer, Wendy Vargas, et al.. (2023). Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies. Neurology and Therapy. 12(3). 883–897. 4 indexed citations
3.
Miller, M. L., et al.. (2022). A 53‐year‐old woman with a rapidly progressive, non‐enhancing left frontotemporal lesion. Brain Pathology. 33(2). e13125–e13125. 1 indexed citations
4.
Jager, Philip L. De, et al.. (2021). Evaluation of ocrelizumab in older progressive multiple sclerosis patients. Multiple Sclerosis and Related Disorders. 55. 103171–103171. 6 indexed citations
5.
Langston, Christopher, Anusha K. Yeshokumar, Michelle Fabian, et al.. (2021). Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses. Multiple Sclerosis and Related Disorders. 56. 103229–103229. 22 indexed citations
6.
Klineova, Sylvia, Asaff Harel, Rebecca Straus Farber, et al.. (2021). Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC). Multiple Sclerosis and Related Disorders. 55. 103153–103153. 12 indexed citations
7.
Xia, Zongqi, Annie Lee, Keith R. Edwards, et al.. (2021). Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data. Multiple Sclerosis and Related Disorders. 57. 103433–103433. 18 indexed citations
8.
Klineova, Sylvia, et al.. (2020). COVID-19 infection in patients with multiple sclerosis: an observational study by the New York COVID-19 neuroimmunology consortium (NYCNIC). Multiple Sclerosis Journal. 26. 78–78. 3 indexed citations
9.
Farber, Rebecca Straus, Kiran T. Thakur, Dina Podolsky, et al.. (2020). Fatal COVID-19 in an MS patient on natalizumab: A case report. Multiple Sclerosis Journal - Experimental Translational and Clinical. 6(3). 2455362899–2455362899. 6 indexed citations
10.
Diaconu, Claudiu, et al.. (2019). Central Meningioma Necrosis after CAR T-Cell Therapy (P2.6-001). Neurology. 92(15_supplement). 1 indexed citations
11.
12.
13.
Klineova, Sylvia, Rebecca Straus Farber, Catarina Saiote, et al.. (2016). Relationship between timed 25-foot walk and diffusion tensor imaging in multiple sclerosis. Multiple Sclerosis Journal - Experimental Translational and Clinical. 2. 2451075333–2451075333. 11 indexed citations
14.
Sand, Ilana Katz, Sergio E. Baranzini, Rob Knight, et al.. (2015). The MS Microbiome Consortium (MSMC): an academic multi-disciplinary collaborative effort to elucidate the role of the gut microbiota in MS (P2.205). Neurology. 84(14_supplement). 1 indexed citations
15.
Chapouly, Candice, Azeb Tadesse Argaw, Sam Horng, et al.. (2015). Astrocytic TYMP and VEGFA drive blood–brain barrier opening in inflammatory central nervous system lesions. Brain. 138(6). 1548–1567. 130 indexed citations
16.
Farber, Rebecca Straus, et al.. (2013). Emergency Department visits before the diagnosis of MS. Multiple Sclerosis and Related Disorders. 3(3). 350–354. 16 indexed citations
17.
Farber, Rebecca Straus, Aaron Miller, Fred Lublin, et al.. (2009). Differentiating multiple sclerosis from other causes of demyelination using diffusion weighted imaging of the corpus callosum. Journal of Magnetic Resonance Imaging. 30(4). 732–736. 10 indexed citations
18.
Farber, Rebecca Straus & James R. Kerrigan. (2006). The Multiple Indications for Growth Hormone Treatment of Pediatric Patients. Pediatric Annals. 35(12). 926–32. 15 indexed citations
19.
Farber, Rebecca Straus, et al.. (2005). Diagnosis of Burkitt lymphoma in pediatric patients by thoracentesis. Pediatric Blood & Cancer. 49(1). 90–92. 4 indexed citations
20.
Pandey, Pramod S., Rebecca Straus Farber, Atsuko Nakazawa, et al.. (2000). Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene. 19(16). 1975–1981. 257 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yanbo Yang Breakdown of academic impact, for papers by Michael D. Carrithers Breakdown of academic impact, for papers by Ferenc Garzuly Breakdown of academic impact, for papers by Barbara Teuchner Breakdown of academic impact, for papers by K.M. Anderson Breakdown of academic impact, for papers by Vera Lehmensiek Breakdown of academic impact, for papers by Mats Ferm Breakdown of academic impact, for papers by Marta Misiuk‐Hojło Breakdown of academic impact, for papers by Kyoko Ishida Breakdown of academic impact, for papers by Junxian Zhang
Rankless by CCL
2026